How to Reopen and Recover a Confirmed Underpayment From a Commercial Payer
Pinpoint the exact contract rate, document every line, and file before the payer's window closes.
A confirmed underpayment on an infusion claim doesn't fix itself. Someone has to catch it, prove it, and push it through a payer's dispute process before the filing window closes, or the money's gone for good. Infusion claims carry extra risk here because the drug line alone, billed separately from administration, can run tens of thousands of dollars on a single date of service. Missing the underpayment, or catching it too late to act, leaves no second chance at recovery.
How infusion remits obscure underpayments at the line level
Most billing systems post a payment and close the claim the moment the remit lands. Staff see "paid," move to the next account, and the claim never gets a second look. That habit is fine for claims paid in full. It fails quietly, every time, on claims paid short, and nobody notices until the filing window is gone.
Infusion claims make this worse because they carry several line types at once: drug lines under J-codes, administration lines under CPT 96xxx codes, and often ancillary charges on top. A correct payment on the administration line can sit right next to a shorted drug line on the same remit, with nothing on the page flagging the difference. Buy-and-bill arrangements add another layer, since commercial payers apply their own fee schedules, fixed percentages of ASP, or AWP-based rates that never appear in plain language on the remit. The biller has to rebuild the contracted rate from scratch, code by code, every time.
Then there's the adjustment code. A contractual write-off applied at the wrong percentage, or against the wrong line entirely, reads exactly like a routine deduction. Nothing on the face of the remit tells the biller that a given adjustment code was applied correctly this time and incorrectly last time.
Payer review technology has added a wrinkle, too. Automated claim review now runs before payment goes out, and it can push payment timelines out several weeks, with high-dollar infusion claims drawing more manual scrutiny than most. So the check that finally lands may already reflect a reduction the payer made on its own, never negotiated, never flagged as a separate action. Without a line-by-line check against the actual contracted rate for each code, these shortfalls blend into the noise of the remit and age past the point where any dispute can still be filed.
Confirming the underpayment before opening a dispute
A dispute needs a confirmed number behind it, and payers will ask for the contractual basis at every step. Get that number nailed down before submitting anything, not after.
Start by pulling the executed contract rate for the exact code and date of service. Fee schedules are frequently tiered by code category, site of care, and payer product line, so a commercial plan rate and a Medicare Advantage rate for the identical J-code can differ. Code, site, and product line all have to match before the comparison means anything.
From there, calculate the variance at the line level: what was billed, what the contract actually requires, what the payer paid, and the dollar gap between required and paid. Cross-check that gap against the 835 remittance to see what adjustment reason the payer cited. A contractual write-off applied correctly and one applied at the wrong percentage look identical on paper, and the dispute has to name which one actually happened.
Authorization needs a look too. If the payer can point to a mismatch between what was authorized and what was billed, that becomes the whole conversation, and the underpayment argument never gets heard. Resolve any PA gap first, or document clearly that none exists. Confirm the payer's dispute filing window while doing this: commercial payers set their own deadlines, commonly somewhere between 90 and 180 days from the remittance date, and those windows shift by payer and by deadline type. Missing it kills the claim no matter how strong the underlying case is.
Finally, line up the clinical record: physician orders, infusion nursing notes with start and stop times, and documentation of the drug units actually administered. The dispute package has to prove the original claim was correct as submitted. Showing it was underpaid isn't enough on its own.
Building the dispute package: what every submission must contain
A dispute package is an evidentiary file, built to answer every objection a reviewer might raise before that reviewer gets the chance to raise it.
The cover letter carries the spine of the argument: claim number, date of service, patient ID, contracted rate, amount paid, amount owed, and the specific contract clause or fee schedule reference proving the shortfall. Attach the ERA/835 extract itself, annotated so the disputed line is impossible to miss. Include the actual contract excerpt, the page and clause governing that code, redacted where needed but clear enough that the rate isn't up for interpretation.
A line-by-line fee schedule calculation belongs in every package: billed code, contracted rate, units, expected payment, actual payment, variance in dollars. Add the clinical documentation, since a payer with a weak financial argument will often pivot to medical necessity instead, and that door needs to be shut in advance. Authorization confirmation (PA number, approval date, approved drug and units, approved site of care) shows the claim stayed inside its approved boundaries. Where a J-code or administration CPT is in dispute, include the code description alongside the specific ASP or AWP quarter used to build the contracted rate.
Documentation gaps are among the more common reasons infusion payments get cut. Incomplete records on medical necessity, start and stop times, or drug units give a payer an opening, and documentation gaps are a well-recognized recurring driver of claim problems across infusion billing. The dispute package needs to close every one of those gaps before the payer gets the chance to open them.
Submit through whatever channel the payer requires, portal, fax, or certified mail, and keep proof of submission with a timestamp. That timestamp is the only evidence, later, that the dispute was filed inside the contractual window.
Navigating the payer's internal dispute and appeal tiers
Commercial payers run this process in tiers: informal reconsideration first, then a formal first-level appeal, then a second-level appeal, then external review or arbitration. Each tier carries its own clock and its own paperwork.
Informal reconsideration is worth trying when the underpayment looks like a plain processing error, such as the wrong fee schedule applied or the code landed in the wrong tier. A correction here skips the whole appeal timeline. First-level appeal means submitting the full dispute package and tracking the payer's response deadline from the date of submission, not the date of service, since payers are required to acknowledge receipt and respond within their stated window.
If that appeal comes back denied, or only partially upheld, get the written rationale in full. The stated reason shapes the entire second-level strategy. A payer claiming no contracted rate exists for the code needs a different response than one claiming the rate was applied correctly when it wasn't. Second-level appeals usually pull in a physician or clinical reviewer on the payer's side. Peer-to-peer conversations earn their keep here, once the objection has shifted toward medical necessity or step therapy.
Step therapy pushback has new legal ground in some states. Connecticut, starting January 1, 2026, bars step therapy outright for MS and RA drugs and caps it at 30 days for other conditions. New Jersey law (C.30:4D-7uu and C.52:14-17.28h, among related sections) requires Medicaid and state employee health programs to grant step therapy exceptions under defined clinical circumstances. Cite either statute directly when step therapy appears as the payer's stated reason for cutting payment.
Every submission, every response, every deadline belongs in a dispute log. Advisory Board puts the average cost of working a denied claim at roughly $118 per appeal. For a high-dollar biologic line, that spend pays for itself many times over, but only if the process keeps moving toward a decision instead of cycling in place.
Escalation paths that still produce payment when internal appeals stall
A stalled appeal doesn't need more pressure applied to the same lever. It needs a different lever.
Provider relations teams operate separately from claims processing at most commercial payers, and a direct escalation to a provider rep, dispute file attached, sometimes breaks loose a claim that's been sitting in an appeal queue going nowhere. Filing a complaint with the state department of insurance is heavier, but effective: it puts the payer on record with a regulator, and payers are required to respond to regulatory inquiries on a set timeline. External independent review is available in most states for certain dispute types, especially where medical necessity is the payer's stated basis, and a reviewer's determination in the provider's favor is typically binding.
Arbitration sits above all of that. Some payer contracts include a binding arbitration clause for payment disputes above a set dollar threshold. In March 2023, an arbitration panel ordered a major insurer to pay Envision Healthcare $91.2 million for violating their reimbursement agreement, proof that arbitration can produce payment after internal appeals go nowhere.
A collective dimension exists too. A $2.8 billion Blue Cross Blue Shield settlement, granted final approval in August 2025, addressed underpayments to hospitals and healthcare organizations at scale. Systemic underpayment patterns sometimes get resolved well beyond any single practice's individual appeals, and practices dealing with the same payer on the same code repeatedly should document that pattern anyway. It may matter for broader dispute activity, or for the next contract negotiation.
Not every claim should be chased to arbitration. Set a per-claim write-off threshold below which escalation stops making financial sense, but never apply that threshold to a biologic line without pricing out the actual drug cost at stake first, not just the billed charge.
The role of payer contract language in whether a dispute is winnable
A dispute only stands as firm as the contract underneath it. Vague or stale rate language hands the payer room to interpret things in its own favor, and payers take that room every time it's offered.
A few contract weaknesses appear repeatedly in infusion disputes. Fee schedules that reference "current" ASP or AWP without naming the specific quarter leave the payer free to pick whichever rate suits them best. Amendments that carve out or exclude certain drug classes or J-codes sometimes never make it into the practice's own billing reference, so the claim gets submitted against an outdated read of the contract. Site-of-care clauses often set a lower rate for hospital-outpatient settings than for freestanding infusion centers, and if the claim's place-of-service code doesn't match reality, the payer's lower rate holds up regardless. Dispute filing windows shorter than 180 days catch practices working off general assumptions instead of that specific payer's terms.
Rate terms deserve a review against actual remit patterns at least once a year. Any gap between what the contract says and what the payer actually pays is either a dispute waiting to be filed, or a signal to push for different terms at the next renegotiation. Recovery work and contract management aren't separate jobs. Findings from one should feed straight into the other.
Prioritizing which underpayments to pursue and in what order
Not every underpayment deserves the same fight. Sequencing is the real skill here: which claims get worked first, hardest, and longest, and which ones wait.
High-dollar biologic lines sit at the top. A single underpaid J-code claim can represent tens of thousands of dollars in drug cost alone, and writing that off is a cash-flow event in its own right. It's a cash-flow event. Just below that: underpayments with a clean contractual basis and a complete clinical record, since those carry the best odds of recovery for the least dispute effort. Recurring underpayments from the same payer on the same code deserve serious attention too, because they point to a systematic fee schedule error, and fixing it once pays off across every claim in that pattern going forward.
Small-dollar variances tied to ambiguous contract language and thin documentation belong at the bottom of the list, or off it. At roughly $118 in cost per appeal, per Advisory Board's figure, the math has to support the effort before the effort gets made.
AR aging changes the order too. A claim approaching its dispute deadline jumps the queue regardless of size, since a missed window kills the claim outright no matter what it's worth. A stale, larger claim only loses its priority once its own deadline risk is under control.
A concentration pattern applies as well. Research on denial and underpayment behavior finds that a small handful of root causes, somewhere in the range of three to five, tends to drive 70 to 80 percent of denials, according to revenue cycle analytics research. A similar concentration pattern often holds for underpayments. Finding which payer-code combinations generate most of the variance tells a practice exactly where a systematic recovery push pays off the most.
Systemic prevention: using recovery findings to stop the next underpayment
Recovering the same underpayment over and over without fixing what causes it is a treadmill, not progress. The same payer applies the same wrong rate to the next claim in that code category unless something changes upstream, and it will keep happening until it does.
Every confirmed underpayment deserves a log entry: payer, date of service, HCPCS/CPT code, contracted rate, paid rate, variance amount, dispute outcome. That log is the dataset that turns individual disputes into a pattern worth acting on. A few signals matter most. The same payer shorting the same code more than once means the conversation needs to move up to the contract level, not stay stuck in claim-by-claim disputes. Underpayments clustering around a specific place-of-service code call for an audit of the claim template used at that site. Recurring shortfalls on a specific J-code mean checking which ASP quarter is actually being applied and confirming the contract clause governing that drug class.
Most of what causes an underpayment gets seeded long before the claim is even submitted, back at scheduling and authorization. By the time billing touches the claim, an authorization mismatch or a wrong place-of-service code is usually already locked in. Catching those problems means building an intake workflow that flags them before treatment happens, not after the remit comes back short.
Infusion-specific revenue cycle operations, built around the authorization-to-remit sequence that infusion actually requires rather than adapted from general billing software, run that feedback loop as a constant habit. Not as a once-a-year audit squeezed in between everything else.
